Sunesis Pharmaceuticals, Inc.  

(Public, NASDAQ:SNSS)   Watch this stock  
Find more results for SNSS
1.21
+0.15 (14.15%)
Aug 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.07 - 1.22
52 week 0.84 - 7.78
Open 1.09
Vol / Avg. 1.04M/2.75M
Mkt cap 91.32M
P/E     -
Div/yield     -
EPS -0.53
Shares 75.47M
Beta 2.07
Inst. own 69%
Nov 9, 2015
Q3 2015 Sunesis Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Aug 12, 2015
Sunesis Pharmaceuticals Inc at Wedbush PacGrow Healthcare Conference
Jul 30, 2015
Q2 2015 Sunesis Pharmaceuticals Inc Earnings Release
Jul 8, 2015
Sunesis Pharmaceuticals Inc at Cantor Fitzgerald Inaugural Healthcare Conference
Jun 12, 2015
Sunesis Pharmaceuticals, Inc. Presentations of VALOR Data - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -1047.89% -749.95%
Operating margin -1243.91% -785.54%
EBITD margin - -785.04%
Return on average assets -87.50% -101.45%
Return on average equity -211.30% -1128.96%
Employees 39 -
CDP Score - -

Address

Suite 400 395 Oyster Point Boulevard
SOUTH SAN FRANCISCO, CA 94080
United States - Map
+1-650-2663500 (Phone)
+1-650-2663501 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company's program is QINPREZOTM (vosaroxin), which is its product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD), which is a class of compounds that has not been used previously for the treatment of cancer. Vosaroxin is an AQD, which is used for the treatment of cancer. MLN2480 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK). PDK1 is a kinase and mediator of PI3K/AKT signaling, which is a pathway involved in cell growth, differentiation, survival and migration.

Officers and directors

Daniel N. Swisher Jr. President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Eric H. Bjerkholt Chief Financial Officer, Executive Vice President - Corporate Development and Finance
Age: 55
Bio & Compensation  - Reuters
Adam R. Craig M.D, Ph.D. Executive Vice President - Development, Chief Medical Officer
Age: 49
Bio & Compensation  - Reuters
James W. Young Ph.D. Non-Executive Independent Chairman of the Board
Age: 70
Bio & Compensation  - Reuters
Stephen B. Ketchum Ph.D. Director
Age: 50
Bio & Compensation  - Reuters
Steve R. Carchedi Independent Director
Age: 53
Bio & Compensation  - Reuters
Matthew K. Fust Independent Director
Age: 50
Bio & Compensation  - Reuters
Helen S. Kim Independent Director
Age: 52
Bio & Compensation  - Reuters